An analysis of the Survival, Epidemiology and End Results database with 18,855 TNBCs and 139,503 non-TNBCs grouped according to their hormone receptor (HR) and HER2 statuses into HR+HER2-, HR+HER2+ and HR-HER2+, showed that the OS of TNBCs was significantly worse for all substages and groups of non-TNBCs with hazard ratios between 1.40 and 4.19 (except for substages IA and IB of HR-HER2+ cancers, where the hazard ratios of 1.21 and 1.76 failed to be significant) [7]. The gene discussed is ERBB2; the disease is cancer.